Myocyte Enhancer Factor 2C as a New Player in Human Breast Cancer Brain Metastases
暂无分享,去创建一个
[1] S. Booth,et al. Downregulation of circulating miR 802‐5p and miR 194‐5p and upregulation of brain MEF2C along breast cancer brain metastasization , 2020, Molecular oncology.
[2] J. Pimentel,et al. Thioredoxin, glutathione and related molecules in tumors of the nervous system. , 2019, Current medicinal chemistry.
[3] C. Brancolini,et al. MEF2 and the tumorigenic process, hic sunt leones. , 2018, Biochimica et biophysica acta. Reviews on cancer.
[4] Chae-Yong Kim,et al. Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort , 2018, The breast journal.
[5] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[6] Yin Lu,et al. Emerging findings into molecular mechanism of brain metastasis , 2018, Cancer medicine.
[7] F. Cardoso,et al. Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015). , 2018, Breast.
[8] Arash Salmaninejad,et al. Organ-specific metastasis of breast cancer: molecular and cellular mechanisms underlying lung metastasis , 2018, Cellular Oncology.
[9] Jia Liu,et al. MEF2 signaling and human diseases , 2017, Oncotarget.
[10] M. Brito,et al. Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall , 2017, Angiogenesis.
[11] M. Videira,et al. Brain metastasization of breast cancer. , 2017, Biochimica et biophysica acta. Reviews on cancer.
[12] D. Yin,et al. Myocyte enhancer factor 2C and its directly-interacting proteins: A review. , 2017, Progress in biophysics and molecular biology.
[13] S. Bates,et al. Current challenges in the management of breast cancer brain metastases. , 2017, Seminars in oncology.
[14] S. P. Herbert,et al. MEF2 transcription factors are key regulators of sprouting angiogenesis , 2016, Genes & development.
[15] Emma Gordon,et al. Mechanisms and regulation of endothelial VEGF receptor signalling , 2016, Nature Reviews Molecular Cell Biology.
[16] Dimitris Basagiannis,et al. Constitutive Endocytosis of VEGFR2 Protects the Receptor against Shedding* , 2016, The Journal of Biological Chemistry.
[17] N. Han,et al. Time course analysis based on gene expression profile and identification of target molecules for colorectal cancer , 2016, Cancer Cell International.
[18] I. Wilhelm,et al. Transmigration characteristics of breast cancer and melanoma cells through the brain endothelium: Role of Rac and PI3K , 2016, Cell adhesion & migration.
[19] A. Vincent-Salomon,et al. Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay , 2016, PloS one.
[20] M. Marra,et al. MEF2 transcription factors: developmental regulators and emerging cancer genes , 2015, Oncotarget.
[21] C. Brancolini,et al. The MEF2–HDAC axis controls proliferation of mammary epithelial cells and acini formation in vitro , 2015, Journal of Cell Science.
[22] F. Winkler. The brain metastatic niche , 2015, Journal of Molecular Medicine.
[23] M. Videira,et al. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. , 2014, Biochimica et biophysica acta.
[24] Qi Zhang,et al. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/β-catenin signaling , 2014, Oncogene.
[25] Weiyu Chen,et al. MEF2 transcription factors promotes EMT and invasiveness of hepatocellular carcinoma through TGF-β1 autoregulation circuitry , 2014, Tumor Biology.
[26] Y. Miao,et al. Yin Yang-1 suppresses invasion and metastasis of pancreatic ductal adenocarcinoma by downregulating MMP10 in a MUC4/ErbB2/p38/MEF2C-dependent mechanism , 2014, Molecular Cancer.
[27] A. Redig,et al. Breast cancer as a systemic disease: a view of metastasis , 2013, Journal of internal medicine.
[28] O. Chinot,et al. Recent trends in epidemiology of brain metastases: an overview. , 2012, Anticancer research.
[29] A. Wells,et al. Mesenchymal–epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer , 2012, Cancer and Metastasis Reviews.
[30] F. Su,et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells , 2011, Molecular Cancer.
[31] C. Perou,et al. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases , 2011, Cancer.
[32] N. Lin,et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer , 2008, Cancer.
[33] E. Duh,et al. Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells. , 2008, Investigative ophthalmology & visual science.
[34] J. Ostrander,et al. Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells. , 2007, Cancer research.
[35] Kay Nieselt,et al. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. , 2006, Cancer research.
[36] N. Copeland,et al. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. , 2005, Blood.
[37] S. Eccles,et al. Breast cancer metastasis: when, where, how? , 2005, The Lancet.